Introduction
The two articles considered here address very different subjects, yet both show why careful interpretation matters when scientific evidence is translated into broader claims. Haghiac et al. (2015) investigated whether long-chain omega-3 fatty-acid supplementation could reduce inflammatory activity in overweight and obese pregnant women, using a randomized, double-masked, placebo-controlled design together with tissue and cell-culture analysis. Pat Shipman’s “Taking the Long View on Sexism in Science” (2015), by contrast, is a reflective essay about the cumulative effects of sexism across a scientific career. The first article asks a mechanistic biomedical question; the second examines institutional culture and unequal power. Neither should be overstated. The omega-3 trial demonstrated changes in inflammatory pathways, not universal protection from pregnancy complications, while Shipman’s personal testimony reveals mechanisms of discrimination without functioning as a population-level prevalence study. Read together, the articles demonstrate two complementary forms of evidence: controlled experimentation can clarify biological mechanisms, while experience and institutional analysis can reveal social processes that may be difficult to capture through a single quantitative measure.
Omega-3 Supplementation in Overweight and Obese Pregnancy
Haghiac et al. began from the observation that overweight and obesity during pregnancy are often associated with heightened metabolic inflammation. Adipose tissue releases signaling molecules that can influence insulin sensitivity, vascular function, placental biology, and maternal metabolism, so the investigators asked whether eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) could reduce selected inflammatory pathways. Participants were randomly assigned to receive 2,000 milligrams per day of long-chain omega-3 fatty acids—1,200 milligrams EPA and 800 milligrams DHA—or placebo beginning between approximately 10 and 16 weeks of gestation and continuing until delivery (Haghiac et al., 2015). The randomized, double-masked design was important because it reduced systematic differences between groups and limited the influence of participant or investigator expectations. Researchers examined blood markers and maternal adipose and placental tissue and also exposed cultured adipose and trophoblast cells to palmitate with or without EPA and DHA. The design therefore connected clinical supplementation with tissue-level and cellular evidence rather than relying on a single blood measurement.
The study found a clear biological response to supplementation. The combined plasma concentration of EPA and DHA increased approximately 5.8-fold in the treated group relative to the comparison group, confirming that the intervention materially changed omega-3 exposure (Haghiac et al., 2015). Plasma C-reactive protein decreased, and adipose and placental tissues from supplemented participants showed lower expression of toll-like receptor 4 and inflammatory cytokines including interleukin-6, interleukin-8, and tumor necrosis factor alpha. In cell experiments, EPA and DHA also suppressed palmitate-induced inflammatory signaling. These results support the proposed mechanism that long-chain omega-3 fatty acids can influence inflammatory pathways in maternal and placental tissues. The finding is stronger than an association because the intervention was randomized and accompanied by biochemical confirmation. At the same time, the primary outcomes were inflammatory markers and molecular pathways. The trial was not designed to prove that supplementation prevents every obesity-related pregnancy complication or guarantees improved fetal or maternal outcomes.
Interpreting the Biological Findings Cautiously
The omega-3 study is useful precisely because it is mechanistic, but that strength also defines its limits. A reduction in a cytokine, receptor, or circulating inflammatory marker can support a biological explanation without establishing a clinically meaningful benefit in every patient. The sample was relatively small, not every participant contributed every tissue specimen, and the trial used a specific high-dose EPA-DHA regimen in women who were overweight or obese. Those features limit generalization to pregnant populations with different diets, medical conditions, body composition, medications, or baseline fatty-acid intake. Larger trials are needed to determine whether anti-inflammatory changes translate consistently into outcomes such as gestational diabetes, preeclampsia, preterm birth, fetal growth, or neonatal health. The study therefore supports a cautious conclusion: more than twenty-five weeks of EPA-DHA supplementation reduced selected inflammatory measures in this population and implicated TLR4 as an important pathway, but it did not create a universal clinical recommendation. Pregnant patients should discuss supplementation with a qualified clinician because dose, product quality, diet, bleeding risk, allergies, medications, and the intended therapeutic goal all matter.
The article also illustrates an important principle in evidence-based medicine: biological plausibility, statistical significance, and clinical usefulness are related but not identical. A well-designed experiment can show that an intervention affects a molecular pathway, yet clinical guidance requires additional information about benefits that patients can feel or measure, adverse effects, comparative effectiveness, feasible dosing, and reproducibility in larger populations. The cell-culture portion strengthens the mechanistic argument because it shows that EPA and DHA can directly suppress palmitate-induced inflammatory signaling under controlled conditions, but laboratory models do not reproduce the full complexity of pregnancy. Likewise, the randomized trial improves causal inference but remains limited by sample size. The most defensible interpretation is therefore neither dismissal nor overenthusiasm. The study provides promising evidence that dietary long-chain omega-3 fatty acids can alter inflammatory activity in overweight and obese pregnancy and justifies further research. It does not support the broader claim that fish-oil supplementation should be prescribed identically to every pregnant woman or treated as a substitute for individualized prenatal care.
Shipman’s Long View on Sexism in Science
Shipman’s essay examines sexism through the accumulation of professional experiences across publishing, mentoring, salary, institutional status, and leadership. Her argument is not structured as an experimental hypothesis but as a historical and experiential claim: scientific institutions can reproduce gender inequality even while presenting themselves as communities governed by objectivity and merit. She describes situations in which women’s competence was questioned, sexual expectations were attached to professional advancement, and compensation was rationalized through assumptions about a husband’s income. The salary example is particularly revealing because it transforms a private stereotype about family roles into an institutional decision about the value of a woman’s work. Shipman also discusses the 2015 controversy surrounding remarks by Nobel laureate Tim Hunt, using the episode not as the sole proof of sexism but as an example of assumptions that can portray women as distractions, emotional problems, or secondary participants in laboratory life. Her wider concern is that isolated incidents become normalized when leadership treats each one as exceptional rather than examining recurring patterns (Shipman, 2015).
Power differences are central to this analysis. A student or junior researcher may depend on one supervisor for laboratory access, authorship, funding, recommendations, degree progress, and future employment. When that supervisor engages in harassment, coercion, or discriminatory evaluation, the relationship is not one between equals. Refusal or complaint can carry professional costs that help explain why misconduct may remain unreported. The National Academies’ 2018 review of sexual harassment in academic science similarly emphasizes that organizational climate, hierarchical dependence, and tolerance of misconduct are major contributors to the problem. Effective prevention therefore requires more than advising individuals to be confident or resilient. Institutions need reporting routes outside the immediate supervisory chain, protection from retaliation, transparent promotion and salary processes, access to alternative mentors, and meaningful consequences when standards are violated. Scientific rigor in experiments does not automatically produce fairness in institutions. Hiring, peer review, authorship, promotion, grant allocation, and mentoring all involve human judgment, making accountability necessary even in professions that explicitly value evidence.
Evidence, Accountability, and Institutional Change
Shipman’s evidence is personal and cumulative rather than statistical, which affects how it should be interpreted. A reflective essay cannot estimate the prevalence of every form of sexism across all scientific fields or prove causation in each institutional decision. That limitation does not make the testimony irrelevant. Personal accounts can identify mechanisms—such as salary assumptions, dependency on supervisors, exclusion from networks, or gendered expectations—that large datasets may record only indirectly. The appropriate response is to combine narrative evidence with salary audits, promotion data, climate surveys, complaint records, authorship patterns, and retention statistics. This approach also avoids the mistake of treating one highly publicized individual as the entire problem. Public condemnation of a remark may signal changing norms, but institutional change requires transparent hiring criteria, equitable compensation, responsible mentoring, parental and caregiving support, independent complaint procedures, and evaluation of whether women actually remain and advance. Progress should therefore be measured by outcomes and organizational behavior rather than by statements of commitment alone.
The essay also challenges a common assumption that scientific achievement protects institutions from social bias. Researchers may use rigorous methods when studying nature yet still participate in workplace cultures shaped by hierarchy, stereotypes, informal networks, and unequal access to sponsorship. Qualification alone does not determine career progression because visibility, recommendations, grants, laboratory assignments, publication opportunities, and leadership selection all influence who advances. Women may therefore encounter a formally open system in which cumulative disadvantages narrow opportunities at successive stages. Shipman’s “long view” is valuable because it shifts attention from whether any one incident can be dismissed to whether similar patterns recur across time and institutional settings. The resulting policy implication is straightforward: responsibility cannot be placed entirely on individuals who experience discrimination. Leaders must examine how authority is distributed, whether complaints can be made safely, whether salaries and promotions are equitable, and whether talented researchers are leaving because the cost of remaining in the system becomes unreasonable.
Comparative Evaluation of the Two Articles
The articles use different forms of evidence, but both reward disciplined interpretation. Haghiac et al. rely on randomized allocation, biochemical measurements, tissue analysis, and controlled cell experiments to establish a plausible anti-inflammatory effect of EPA and DHA in a defined group of pregnant women. Their strongest claims are narrow and mechanistic. Shipman uses professional memory and institutional observation to expose how inequality can operate through decisions about salary, supervision, publication, and authority. Her strongest claims concern patterns and mechanisms rather than numerical prevalence. In both cases, overstatement would weaken the analysis. A biomarker change should not become a universal treatment recommendation, and a personal essay should not be presented as if it were a randomized survey of the scientific workforce. At the same time, excessive skepticism would also be mistaken. The omega-3 trial provides legitimate causal evidence within its scope, while Shipman’s experiences are legitimate evidence about institutional processes that can be tested and contextualized with broader research. Good academic reading therefore requires matching conclusions to the type, scale, and limitations of the evidence.
Conclusion
Haghiac et al. demonstrate that EPA and DHA supplementation can reduce selected inflammatory signals in maternal adipose tissue, placenta, blood, and relevant cell models among overweight and obese pregnant women, with TLR4 emerging as an important mechanistic target. The study is strengthened by randomization, masking, placebo comparison, biochemical verification, and multiple levels of analysis, but its small sample and biomarker-centered outcomes require caution when translating the findings into clinical practice. Shipman’s essay addresses a different scientific problem: the persistence of sexism within institutions that publicly value objectivity. Her long-term account shows how unequal pay, harassment, exclusion, and supervisory power can shape careers even when formal rules appear neutral. The two articles therefore illustrate complementary lessons about evidence. Biomedical claims should not outrun the design of a study, and institutional claims should be examined through both testimony and organizational data. Scientific integrity depends not only on accurate measurement in the laboratory but also on careful interpretation and on institutions willing to examine how power affects the people who produce knowledge.
References
Haghiac, M., Yang, X. H., Presley, L., Smith, S., Dettelback, S., Minium, J., Belury, M. A., Catalano, P. M., & Hauguel-de Mouzon, S. (2015). Dietary omega-3 fatty acid supplementation reduces inflammation in obese pregnant women: A randomized double-blind controlled clinical trial. PLOS ONE, 10(9), e0137309. https://doi.org/10.1371/journal.pone.0137309
National Academies of Sciences, Engineering, and Medicine. (2018). Sexual harassment of women: Climate, culture, and consequences in academic sciences, engineering, and medicine. National Academies Press.
Shipman, P. (2015). Taking the long view on sexism in science. American Scientist, 103, 392–394.
Cite This Work
To export a reference to this article please select a referencing stye below:
Academic Master Education Team is a group of academic editors and subject specialists responsible for producing structured, research-backed essays across multiple disciplines. Each article is developed following Academic Master’s Editorial Policy and supported by credible academic references. The team ensures clarity, citation accuracy, and adherence to ethical academic writing standards
Content reviewed under Academic Master Editorial Policy.
